After years of disappointing clinical trials for nonalcoholic steatohepatitis (NASH), an often fatal liver disease associated with obesity and diabetes, there are a number of promising late-stage clinical trials underway, including two being conducted by pending biotech IPOs Cirius Therapeutics (CSTX) and Genfit (GNFT). NASH affects 20 million people with no FDA-approved therapies and is a multi-billion dollar opportunity.
Cirius recently reported positive interim results in a Phase 2 trial for its once daily oral small molecule that is a selective modulator of mitochondrial metabolism. It has enrolled a Phase 2b trial that will be the basis for designing a larger pivotal trial...
To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.
